These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22712224)

  • 1. [Botulinum toxin in the treatment of cerebral palsy: case conference].
    Nezu A; Adachi M
    No To Hattatsu; 2012 May; 44(3):225-7. PubMed ID: 22712224
    [No Abstract]   [Full Text] [Related]  

  • 2. [Botulinum toxin in the treatment of cerebral palsy--case conference].
    Nezu A; Iai M
    No To Hattatsu; 2010 May; 42(3):230-2. PubMed ID: 23858585
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with botulinum toxin in the treatment of cerebral palsy.
    Arens LJ; Leary PM; Goldschmidt RB
    S Afr Med J; 1997 Aug; 87(8):1001-3. PubMed ID: 9323408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review.
    Gormley ME; Gaebler-Spira D; Delgado MR
    J Child Neurol; 2001 Feb; 16(2):113-8. PubMed ID: 11292216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Botulinum toxine treatment and the formation of antibodies to botulotoxin in patients with cerebral palsy].
    Kenis VM; Baindurashvili AG; Dovbeshko AG; Korol'kova TN; Ivanov AM; Stepanova IuA; Protasov OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9):48-51. PubMed ID: 22027670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
    Yang TF; Fu CP; Kao NT; Chan RC; Chen SJ
    Am J Phys Med Rehabil; 2003 Apr; 82(4):284-9. PubMed ID: 12649654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A in children and adolescents with severe cerebral palsy: a retrospective chart review.
    Mesterman R; Gorter JW; Harvey A; Lockhart J; McEwen-Hill J; Margallo K; Goldie N
    J Child Neurol; 2014 Feb; 29(2):210-3. PubMed ID: 23965398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review.
    Edgar TS
    J Child Neurol; 2001 Jan; 16(1):37-46. PubMed ID: 11225955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Question 2: is there any long-term benefit from injecting botulinum toxin-A into children with cerebral palsy?
    Bradley LJ; Huntley JS
    Arch Dis Child; 2014 Apr; 99(4):392-4. PubMed ID: 24626322
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of children with cerebral palsy.
    Dai AI
    J Pediatr Orthop B; 2007 Jul; 16(4):303. PubMed ID: 17527111
    [No Abstract]   [Full Text] [Related]  

  • 11. Functional outcomes of multilevel botulinum toxin and comprehensive rehabilitation in cerebral palsy.
    Balbaloglu O; Basaran A; Ayoglu H
    J Child Neurol; 2011 Apr; 26(4):482-7. PubMed ID: 21270468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Botulinum Toxin Type A Injection Followed by Rehabilitation in Cases of Cerebral Palsy With Upper Extremity Involvement.
    Karaca B; Ünlü E; Köse G; Gönen E; Çakcı A
    J Child Neurol; 2016 Mar; 31(3):357-63. PubMed ID: 26239492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are the long-term consequences of botulinum toxin injections in spastic cerebral palsy?
    Barrett RS
    Dev Med Child Neurol; 2011 Jun; 53(6):485. PubMed ID: 21518344
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of a framework to define the functional goals and outcomes of botulinum toxin A spasticity treatment relevant to the child and family living with cerebral palsy using the International Classification of Functioning, Disability and Health for Children and Youth.
    Preston N; Clarke M; Bhakta B
    J Rehabil Med; 2011 Nov; 43(11):1010-5. PubMed ID: 22031347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No change in calf muscle passive stiffness after botulinum toxin injection in children with cerebral palsy.
    Alhusaini AA; Crosbie J; Shepherd RB; Dean CM; Scheinberg A
    Dev Med Child Neurol; 2011 Jun; 53(6):553-8. PubMed ID: 21574991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany.
    Ruiz FJ; Guest JF; Lehmann A; Davie AM; Güttler K; Schlüter O; Dreiss G
    Eur J Health Econ; 2004 Oct; 5(3):227-35. PubMed ID: 15714343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of spasticity in children with cerebral palsy with botulinum toxin A].
    Madsen ES; Sonne-Holm S; Wong C; Curtis D; Bencke J
    Ugeskr Laeger; 2015 Jan; 177(3):V07140409. PubMed ID: 25613095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Botulinum toxin in the treatment for cerebral palsy].
    Nezu A; Otsuka Y
    No To Hattatsu; 2009 Mar; 41(2):129-31. PubMed ID: 19517779
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of botulinum toxin in the treatment of ankle plantar flexor spasticity in children with cerebral palsy.
    Mirska A; Cybula K; Okurowska-Zawada B; Kułak W; Dmitruk E; Okulczyk K; Kalinowska AK
    J Pediatr Orthop B; 2014 Nov; 23(6):517-22. PubMed ID: 25171568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin for the treatment of spasticity in children: attainment of treatment goals.
    Weigl DM; Arbel N; Katz K; Becker T; Bar-On E
    J Pediatr Orthop B; 2007 Jul; 16(4):293-6. PubMed ID: 17527109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.